Stuart Chaussee & Associates Inc. Takes $33,000 Position in Takeda Pharmaceutical Co Ltd (TAK)

Share on StockTwits

Stuart Chaussee & Associates Inc. acquired a new position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,636 shares of the company’s stock, valued at approximately $33,000.

Other large investors also recently bought and sold shares of the company. Hudock Capital Group LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $26,000. Contravisory Investment Management Inc. acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $28,000. Shine Investment Advisory Services Inc. acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $28,000. Parallel Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $33,000. Finally, First Hawaiian Bank acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $35,000. Institutional investors own 4.42% of the company’s stock.

Shares of NYSE TAK traded up $0.61 during midday trading on Monday, hitting $18.08. The company’s stock had a trading volume of 19,592 shares, compared to its average volume of 2,781,687. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.81 and a current ratio of 1.22. Takeda Pharmaceutical Co Ltd has a 1 year low of $15.50 and a 1 year high of $21.95. The firm has a market cap of $27.29 billion, a price-to-earnings ratio of 16.92 and a beta of 0.66.

A number of equities research analysts have recently commented on TAK shares. Goldman Sachs Group reiterated a “buy” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, March 19th. Zacks Investment Research lowered shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, April 27th. Finally, ValuEngine lowered shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th.

TRADEMARK VIOLATION WARNING: “Stuart Chaussee & Associates Inc. Takes $33,000 Position in Takeda Pharmaceutical Co Ltd (TAK)” was originally reported by Highlight Press and is owned by of Highlight Press. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://highlightpress.com/2019/05/20/stuart-chaussee-associates-inc-takes-33000-position-in-takeda-pharmaceutical-co-ltd-tak.html.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Article: NASDAQ

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.